Sinovac Biotech Co., Ltd: all 163 studies

Page 1 of 2. Open to participants first (37), then studies with results posted, then the rest; newest registration first within each.

• Study on the Long-Term Persistence of Immunity Induced by Inactivated Hepatitis A VaccineRecruitingNCT07889219
• Phase I Clinical Trial of Trivalent Inactivated Split Influenza Virus Vaccine (MDCK Cell)Not yet recruitingNCT07889193Phase 1
• A Lot-to-Lot Consistency Clinical Trial of PCV13Not yet recruitingNCT07832500Phase 3
• A Phase IV Clinical Trial of Influenza Vaccine (Split Virion), Inactivatedin (Anflu®) Pregnant Women (AnFLU-PREG)Not yet recruitingNCT07832201Phase 4
• Phase Ⅲ Clinical Trial of an Inactivated Hepatitis A VaccineRecruitingNCT07793227Phase 3
• Bridging Clinical Trial of EV71 Vaccine in Vietnamese ChildrenNot yet recruitingNCT07793175Not applicable
• A Phase Ⅲ Clinical Study of SNA02-48 InjectionNot yet recruitingNCT07633119Phase 3
• Protective Efficacy , Immunogenicity and Safety of the Tetravalent Inactivated Enterovirus Vaccine (Vero Cell).Not yet recruitingNCT07611513Phase 3
• Clinical Trial of PCV13 in Infants Aged Approximately 2 Months (42 to 89 Days)Not yet recruitingNCT07593924Phase 3
• Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 MonthsRecruitingNCT07505836Phase 3
• Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 6-11 MonthsRecruitingNCT07505823Phase 3
• Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 3-5 MonthsRecruitingNCT07505810Phase 3
• Second Dose of Varicella Vaccine in Healthy ChildrenRecruitingNCT07475000Phase 3
• Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese ChildrenNot yet recruitingNCT07473427Phase 3
• Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus VaccineRecruitingNCT07457060Phase 4
• Study to Evaluate the Safety of a Lyophilized RSV mRNA VaccineNot yet recruitingNCT07418229Phase 1
• Phase IIIb Clinical Trial to Evaluate Lot-to-lot Consistency of Sinovac Rabies VaccineNot yet recruitingNCT07416110Phase 3
• Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA VaccineRecruitingNCT07400003Phase 1/2
• Phase Ia Clinical Trial of Group ACYW135X Meningococcal Conjugate VaccineNot yet recruitingNCT07374510Phase 1
• Phase IV Clinical Study of sIPV Administration in Adolescent and Adult PopulationsRecruitingNCT07354269Phase 4
• Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 YearsRecruitingNCT07300644Phase 2
• Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis RegimenNot yet recruitingNCT07055893Phase 3
• Immunogenicity and Safety of Different Dosages of Rabies Vaccine (Serum-free Vero Cell)Not yet recruitingNCT07055880Phase 2
• Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Prophylaxis RegimenNot yet recruitingNCT07055295Phase 3
• PhaseⅡClinical Trial of Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)RecruitingNCT06967272Phase 2
• Study of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP VaccineNot yet recruitingNCT06891872Phase 4
• Clinical Trial of PCV24 in Infants Aged 2-23 MonthsRecruitingNCT06800261Phase 1
• Efficacy, Safety, and Immunogenicity of the Bivalent Inactivated Enterovirus Vaccine (Vero Cell)RecruitingNCT06734832Phase 3
• Clinical Trial of 13-Valent Pneumococcal Conjugate VaccineRecruitingNCT06617715Phase 3
• An Immunity Persistence Study of Booster Dose of Live Attenuated Varicella VaccineEnrolling by invitationNCT06484686Phase 4
• Correlation of Protection Against Varicella in an Exploratory StudyNot yet recruitingNCT06482216
• Active Case Finding of Clinical Hand Foot Mouth Disease in Children Aged 6 Months Old to 18 Years Old in IndonesiaNot yet recruitingNCT06251219
• SA55 Injection: a Potential Therapy for the Prevention and Treatment of COVID-19RecruitingNCT06050460Phase 1
• SA55 Novel Coronavirus Broad-spectrum Neutralizing Antibody Nasal Spray in Health PeopleRecruitingNCT06048393Phase 1
• SA55 Injection Phase II Study in the Treatment of Mild/Moderate COVID-19 PatientsRecruitingNCT06042764Phase 2
• An Immunity Persistence Study of Live Attenuated Varicella VaccineEnrolling by invitationNCT05095701Phase 4
• Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years OldEnrolling by invitationNCT05015686Phase 3
• A Study to Evaluate the 17-Year Immune Persistence of a Single Dose of Inactivated Hepatitis A VaccineCompletedNCT07855705
• Phase I Clinical Trial of Influenza Vaccine (Split Virion), Inactivated (High Dose)CompletedNCT07737106Phase 1
• Clinical Trial of PCV24 in Adults Aged ≥18 YearsCompletedNCT07543198Phase 1/2
• Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 YearsActive, not recruitingNCT07505888Phase 3
• Immunogenicity and Safety Assessment of Rabies Vaccine (Vero Cell) for Human Use, Freeze-driedCompletedNCT07357545Phase 3
• Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant WomenCompletedNCT07211152Phase 3
• A Clinical Trial to Observe the Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Target PopulationCompletedNCT07071701
• Clinical Trial for Batch Consistency of EV71 VaccineCompletedNCT07026500Phase 4
• Study on Booster Immunization With Varicella Vaccine at Different IntervalsCompletedNCT06994052Phase 4
• Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion)CompletedNCT06987942Phase 4
• The Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)CompletedNCT06950645Phase 1
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult ParticipantsCompletedNCT06939777Phase 1/2
• Tolerability, Safety, and Immunogenicity of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell).CompletedNCT06754384Phase 1/2
• Clinical Trial of PCV24 in Children Aged 2-17 YearsCompletedNCT06550830Phase 1
• Clinical Trial of PCV24 in AdultsCompletedNCT06474377Phase 1
• Booster Dose of sIPV Co-administered With MMR and HepA-I.CompletedNCT06442449Phase 4
• Sequential Vaccination of Poliomyelitis Vaccine (Vero Cells), Inactivated, Sabin Strains From Different ManufacturersCompletedNCT06346834Phase 4
• Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the PhilippinesCompletedNCT06314724Phase 3
• The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School StudentsActive, not recruitingNCT06208683Phase 4
• A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate VaccineCompletedNCT06183216Phase 1
• Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical TrialCompletedNCT06063057Phase 1/2
• Immunogenicity of After Primary Immunization and Booster Immunization of sIPVActive, not recruitingNCT06058429
• Immunogenicity and Safety of Hepatitis A Among People Aged 18-50 Years OldActive, not recruitingNCT06058416Phase 4
• Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old PopulationCompletedNCT06049940Phase 3
• A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 MonthsCompletedNCT06049927Phase 3
• A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinical Trial of sIPV VaccineCompletedNCT05850364Phase 3
• Lot-to-lot Consistency of 23-valent Pneumococcal Polysaccharide VaccineCompletedNCT05731115Phase 4
• Efficacy and Safety of SA58 Nasal Spray in Close Contact With COVID-19 PeopleStatus unknownNCT05667714Not applicable
• Efficacy and Safety of Anti-COVID-19 Antibody SA58 Nasal Spray to Prevent Infection in High-risk PopulationsStatus unknownNCT05664919Not applicable
• A Serosurvey Study of Hand, Foot, and Mouth Disease in IndonesiaCompletedNCT05637229
• A Study of Combined Immunization With Live Attenuated Varicella Vaccine and Inactivated Hepatitis A VaccineCompletedNCT05526820Phase 4
• Lot-to-lot Consistency of Quadrivalent Influenza Vaccine (Split Virion), InactivatedCompletedNCT05512494Phase 4
• A Study of Booster Immunization With COVID-19 Vaccine,Inactivated Co -Administration With Influenza Vaccine and Pneumococcal Polysaccharide VaccineCompletedNCT05499351Phase 4
• Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide VaccineCompletedNCT05477693Phase 4
• Study on Combined Vaccination With Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Polysaccharide VaccineCompletedNCT05471531Phase 4
• Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui ProvinceStatus unknownNCT05470855Phase 4
• Immunogenicity, Safety and Protective Effect of Live Attenuated Varicella Vaccine and Study on Antibody Level and Etiology of Varicella Zoster VirusStatus unknownNCT05460429Phase 4
• Immunogenicity and Safety Study of One Booster Dose of Trivalent COVID-19 Vaccine (Vero Cell), InactivatedStatus unknownNCT05433272Phase 3
• A Safety Study of Sabin Inactivated Poliovirus Vaccine in InfantsCompletedNCT05432141Phase 4
• Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, QuadrivalentCompletedNCT05431725Phase 3
• Immunogenicity and Safety Study of Booster Vaccine With the COVID-19 Vaccine (Vero Cell), Inactivated, Omicron StrainCompletedNCT05411471Phase 2
• Immunogenicity and Safety of a Third Dose of COVID-19 Vaccine(Vero Cell), Inactivated in the ElderlyCompletedNCT05398926Phase 4
• An Immunity Persistence Study of Enterovirus 71 Inactivated Vaccine (Vero Cell)Status unknownNCT05397587Phase 4
• Safety of Sabin Inactivated Poliovirus Vaccine in Adults, Children and Infants and Lot Consistency Immunogenicity, and Safety of the msIPV in 2 Months Old InfantsCompletedNCT05386810Phase 3
• Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and AboveCompletedNCT05381350Phase 3
• Effectiveness of Inactivated COVID-19 Vaccine of the First Booster DoseStatus unknownNCT05367895
• Immunogenicity，Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 VaccineActive, not recruitingNCT05329038Phase 4
• Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated Vaccine in Healthy Adults in in Hong KongWithdrawnNCT05254236Phase 2
• A Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 MonthsCompletedNCT05245552Phase 3
• Immunogenicity of an Inactivated COVID-19 VaccineCompletedNCT05198336Phase 4
• Safety Observation of Enterovirus 71 Inactivated Vaccine (Vero Cell) Combined Immunization in ShanghaiStatus unknownNCT05166044
• Safety and Immunogenicity Study of Booster Vaccination in Different Doses of COVID-19 Vaccine (Vero Cell),Inactivated for Prevention of COVID-19CompletedNCT05165966Phase 4
• Safety and Immunogenicity Study of Booster Vaccination With COVID-19 Vaccine (Vero Cell),Inactivated From Different Manufactures for Prevention of COVID-19SuspendedNCT05165732Phase 4
• Efficacy,Immunogenicity and Safety of COVID-19 Vaccine , Inactivated Booster Dose in Adults Aged 18 Years and AboveWithdrawnNCT05156632Phase 3
• Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults in TurkeySuspendedNCT05150496Phase 2
• An Open-labelled Clinical Trial of Live Attenuated Varicella Vaccines to Evaluate the Immunity Persistence After Primary Immunization and Safety and Immunogenicity After the Booster ImmunizationCompletedNCT05150392Phase 3
• Safety Study of Live Attenuated Mumps Vaccines in Junior High School Students Under 14 Years OldCompletedNCT05145166
• Safety and Immunogenicity of COVID-19 Vaccine, Inactivated in Healthy Population Aged From 3 to 11 YearsCompletedNCT05137418Phase 3
• Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different Workshops in Healthy Children Aged 3-17 YearsActive, not recruitingNCT05112913Phase 4
• Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)CompletedNCT05107557Phase 4
• Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate VaccineCompletedNCT05092386Phase 1
• Safety and Immunogenicity Study of Booster Vaccination With Medium-dosage or High-dosage SARS-CoV-2 Inactivated Vaccine for Prevention of COVID-19Status unknownNCT05079217Phase 4
• Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy InfantsCompletedNCT05065177Phase 3

← Sinovac Biotech Co., Ltd overview and focus areas